Group 1: Overall Business Performance - In the first half of 2025, the company achieved a revenue of 2.042 billion, a year-on-year increase of 2.57% [3] - Net profit attributable to shareholders increased by 1.61% to 0.430 billion [3] - Revenue from the China region decreased by 1.63% to 0.818 billion, while overall order growth outpaced revenue growth [4] Group 2: International Expansion - The Americas region generated revenue of 0.760 billion, a year-on-year growth of 4.26% [4] - The European region achieved revenue of 0.359 billion, with a significant increase of 21.96% [4] - Other regions reported a revenue of 0.105 billion, reflecting a decline of 22.91% due to low base effects [4] Group 3: Product Performance - Soft capsule revenue grew by 6.5% in the first half of 2025, driven by product innovation and operational optimization [6] - The gummy business continued its growth trend with a revenue increase of 6.4%, supported by rising global demand and collaboration with well-known brand clients [7] - Tablet revenue surged by 33.4%, capitalizing on business growth opportunities [7] Group 4: Financial Metrics - The company's gross margin improved year-on-year, attributed to lean production and continuous cost reduction efforts [8] - Operating cash flow increased by 39.7%, significantly outpacing revenue growth, indicating strong cash flow management [8] Group 5: Strategic Initiatives - The company is focusing on advanced technology development and smart supply chain systems to enhance productivity in the nutrition and health industry [6] - Efforts are underway to optimize the BF business structure through potential investments or strategic partnerships [5]
仙乐健康(300791) - 2025年8月25日 投资者关系活动记录表